MAXHEALTHHealthcare

Max Healthcare Institute Limited

Hospital · ISIN INE027H01010 · BSE 543220 · NSE EQ · FV ₹10
Last price
₹1,037
+1.17%today
What this company does

Max Healthcare Institute Limited operates in Hospital, part of the Healthcare sector. It booked ₹2,366 cr of revenue in its latest quarter (Q1 FY27) and kept 13.6% of sales as profit. It is the 2nd largest of 9 Hospital companies we track, by market value.

50out of 100
Equitytale Health Score
Mixed

Healthier than 50% of companies in Healthcare, on all six measures of filed financials. Each measure is ranked against the 81–150 companies that reported it.

Measures financial condition, not whether to buy. Learn what this score means · How this is calculated

Price momentum
neutral
RSI (14)
53

At close. Not part of the score.

Profitability & returns49

How much profit it earns on the money it employs

Balance sheet32

How much it owes, and whether earnings cover the interest

Cash quality70

Whether reported profit actually arrives as cash

Growth & consistency68

Whether sales and profit have grown, and how steadily

Valuation17

What today's price implies, against our models or its peers

Governance & risk86

How much of the promoters' stake is pledged, and how much they hold

Is this company doing well?
not investment advice
Strengths
Makes a profit
Sales up 17% vs last year
No promoter shares pledged
Turns profit into real cash
Watch-outs
None flagged from our data

What if I invest in MAXHEALTH?

Set a growth rate and see what a monthly SIP would add up to. Your assumption, our arithmetic.

You would put in
₹12.00 lakh
120 instalments
At 10% a year, it would become
₹20.15 lakh

The starting rate is a round number, not a view on this company — this is your assumption, and the figure above is arithmetic on it. Returns are not steady year to year, and a real holding would not grow in a straight line. We do not publish price targets or predict returns.

Key ratios · latest quarter + price
₹1,037 +1.17%
latest close · 2026-09-17
1-year return
+211.1%
52-wk low ₹32252-wk high ₹1,136
Is it cheap or expensive?
What you pay for the profits, book value and cash flow. Higher isn't automatically worse — it can signal faster growth.
P/E ratio78.1High
LowAverageHigh
P/B ratio9.39High
Below bookModerateHigh
EV / EBITDA40.6High
LowAverageHigh
How good is the business?
How much profit it earns from its money and its sales.
Return on equity12.0%Fair
WeakFairStrong ▸15%
Return on capital13.5%Fair
WeakFairStrong
Net margin13.6%Decent
ThinDecentStrong
EBITDA margin27.0%Healthy
ThinDecentHealthy
Is it financially safe?
How much it owes, and whether it can comfortably cover it.
Debt to equity0.32Comfortable
LowModerateHigh ▸1
Interest cover7.1×Strong
RiskyOkayStrong ▸5×
Current ratio0.89Tight
Tight ◂1HealthyAmple
More figures
Market cap
₹1.01 L cr
Book value
₹110
EPS
₹3.32
latest quarter
Net debt
₹2,813 cr
owes more than its cash
Enterprise value
₹1.04 L cr
EBITDA
₹2,556 cr
annualised
EBIT
₹2,029 cr
annualised
Operating margin
21.4%
Return on assets
7.5%
Earnings yield
1.28%
P/S
10.66
Sales / share
₹97.2
Tax rate
26.0%
Face value
₹10
Shares
97.3 cr
Working capital
₹-242 cr
Current assets
₹1,945 cr
Current liabilities
₹2,187 cr
Delivery %
56.9%
Strong / safeFairWeak / riskyValuation — a level, not good/badBands are general rules of thumb, not advice.

P/E, ROE, ROCE and margins are annualised from the latest quarter; per-share and balance-sheet ratios use the most recent balance sheet on file · prices as of 2026-09-17.

Worth vs price · from the exchange filings
not investment advice
Hard to value confidentlyLow confidence
The market price is far above what these earnings- and book-based models support — a fast-growing or asset-light business can trade well above them for years, so we won't put a confident number on how overpriced it is.
Models span ₹99₹165, midpoint ₹134

An educational model from the company's own filings, every assumption shown — not investment advice or a price target. Prices can stay above or below any model for years.

P&L · Q1 FY27 (consolidated)
Revenue from Operations₹2,366 cr
Other Income₹41 cr
Total Income₹2,407 cr
Cost of Materials₹0 cr
Purchases of Stock-in-Trade₹521 cr
Inventory Change (±)₹-8 cr
Employee Benefit Expense₹388 cr
Finance Costs₹71 cr
Depreciation & Amortisation₹132 cr
Other Expenses₹866 cr
Total Expenses₹1,970 cr
Profit before Tax₹436 cr
Tax Expense₹113 cr
Net Profit₹323 cr
Net margin on total income13.4%
Where the money goes · Q1 FY27
% of total income
Materials + stock-in-trade₹513 cr21.3%
Employee benefit expense₹388 cr16.1%
Finance costs₹71 cr3.0%
Depreciation & amortisation₹132 cr5.5%
Other expenses₹866 cr36.0%
Tax expense₹113 cr4.7%
Profit for the period₹323 cr13.4%
Total income ₹2,407 cradds up to ₹100 ✓
Quarterly results · consolidated (₹ cr)
MetricQ3 FY26Q4 FY26Q1 FY27
Revenue2,068 cr2,143 cr2,366 cr
Total income2,113 cr2,191 cr2,407 cr
Expenses1,700 cr1,726 cr1,970 cr
Profit before tax365 cr465 cr436 cr
Tax64 cr122 cr113 cr
Net profit (owners' share)301 cr342 cr323 cr
Net margin (owners' share, on revenue)14.6%16.0%13.6%
EPS (₹)3.103.523.32
YoY (latest quarter): total income +16.6% · net profit +4.9%
Balance sheet & cash flow · as of Mar 2026
Low debt
Total assets
₹17,231 cr
Shareholder equity
₹10,747 cr
parent shareholders
Total debt
₹3,478 cr
Cash
₹666 cr
Cash flow · H1 FY26
Operating
₹818 cr
Investing
₹-966 cr
Financing
₹-35 cr
Peer comparison
Hospital · by market value
CompanyPriceMarket capP/E
Apollo Hospitals Enterprise Limited₹8,769₹1.26 L cr54.3
Max Healthcare Institute Limitedthis company₹1,037₹1.01 L cr78.1
Manipal Health Enterprises Limited₹722₹85,125 cr92.0
Fortis Healthcare Limited₹886₹66,897 cr62.8
Aster DM Quality Care Limited₹761₹39,412 cr613.4
Global Health Limited₹1,424₹38,273 cr60.2
Narayana Hrudayalaya Ltd.₹1,869₹38,187 cr45.8
Krishna Institute of Medical Sciences Limited₹792₹33,258 cr190.3
Dr. Agarwal's Health Care Limited₹500₹15,855 cr87.4
Same industry · latest reported numbers · not a recommendation.
Corporate actions
Dividend yield
0.19%
trailing 12 months
Dividend / share (TTM)
₹2
Last dividend
₹2
ex 3 Jul 2026
ActionDetailEx-date
Dividend₹2 / share3 Jul 2026
Dividend₹1.5 / share4 Jul 2025
Dividend₹1.5 / share23 Aug 2024
Dividend₹1 / share8 Sep 2023
Who owns it · 2026-06-30
No pledge
Promoter
23.7%
FII / Foreign
41.8%
DII / Domestic
30.0%
Retail / others
4.6%
Promoter stake down 0.1% over the last 12 quarters.
Smart-money activity
Insider trades
SoldKayak Investments Holding Pte. Ltd. · Promoters68.74 L · ₹6,88025 Aug 22
BoughtAbhay Soi · Promoters68.74 L · ₹6,88025 Aug 22
SoldKayak Investments Holding Pte. Ltd. · Promoters26.02 cr · ₹9185.8 cr16 Aug 22
Bulk / block deals
short · NSE4310 Sep 26
short · NSE3049 Sep 26
short · NSE112 Aug 26
Stake changes
SoldNew World Fund, Inc.→ 4.72% · 1.95 cr29 Sep 25
SoldGIC Private Limited (GIC) on account of the Monetary Authority of Singapore (MAS)→ 1.30% · 1.76 L18 Sep 25
SoldGIC Private Limited (GIC) on account of Government of Singapore (GOS)→ 4.50% · 7.85 L18 Sep 25
Promoter pledges
PledgedFinance Parties11.29 cr · 0.00% held8 Oct 21
PledgedAxis Trusteeship Services Limited as Onshore Security Agent25.11 cr · 0.00% held6 Oct 21
ReleasedLender KKR India Financial Services Ltd Trustee IDBI Trusteeship Services Ltd1.17 cr · 1.29% held24 Sep 20
What shareholders were asked to approve

A company cannot decide everything on its own. Things like a top executive’s pay, issuing new shares, or re-appointing a director have to be put to the people who own the company, and they vote — one vote per share. So whoever owns the most shares has the most say.

Yearly shareholder meeting · 30 Jul 2025
See the official result
1
Adoption of Audited Standalone Financial Statements for the financial year 2024-25
Backed by 100% of shareholders other than promotersneeded 50%
64.67 cr votes for, 13 against · 0% of mutual funds and other big investors said no
2
Adoption of Audited Consolidated Financial Statements for the financial year 2024-25
Backed by 100% of shareholders other than promotersneeded 50%
64.67 cr votes for, 12 against · 0% of mutual funds and other big investors said no
3
Declaration of final Dividend of ₹1.5 (i.e. 15%) per equity share of face value of ₹10 each
Backed by 100% of shareholders other than promotersneeded 50%
65.20 cr votes for, 11 against · 0% of mutual funds and other big investors said no
4
Appointment of Director in place of Mr. Anil Kumar Bhatnagar, who retires by rotation and being eligible offers himself for re-appointment
Promoters had a personal stake in this
Backed by 98% of shareholders other than promotersneeded 50%
64.13 cr votes for, 1.06 cr against · 2% of mutual funds and other big investors said no

Every vote count above is taken from the result the company filed with the stock exchange, certified by an independent counter. To work out what would have happened without the promoters, we simply remove their votes and re-apply the same legal bar the proposal had to clear. Nothing here is an estimate or an opinion.

Who controls this company, and what it pays them

Most Indian companies are controlled by a family or group — the promoters. The exchange requires them to be listed by name, including members who own no shares at all, and requires the company to disclose any business it does with them.

The promoter group — 17 named members
owning 23.7% between them · as of 2026-06-30
Abhay Soi23.71%
Aditya Soi0.01%
Aeshani Soino shares
Akhil Sarup Bhatnagarno shares
Anil Kumar Bhatnagarno shares
Bulbul Soino shares
Devina Soino shares
Devshan International LLPno shares
Business done with them
FY2026 · 2 of the group
The company paid ₹66 cr to companies in the promoter group last year — about 0.8% of its ₹8,373 cr revenue.
Mr. Abhay Soi
Other payments to them · Description is mentioned along with relevant item
also owns 23.71% of the company
₹63 cr
company paid
Mr. Aditya Soi
Other payments to them · Description is mentioned along with relevant item
also owns 0.01% of the company
₹4 cr
company paid

The company also transacted with 9 other related parties — subsidiaries, joint ventures, directors and others — that we could not match by name to the promoter list above. Some may still be connected to the family; we only count the ones the filings let us match with certainty.

Names and holdings from the company’s shareholding pattern filed with the exchange; transactions from the related-party note in its annual report. Every figure is as filed — these are legal, disclosed dealings, and what to make of them is your call.

How the stock has moved · adjusted for splits & bonuses
Data from primary exchange filings · analysis tool, not investment advice.